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TRPV2Transient receptor potential vanilloid (TRPV) 1 channels function as sensors for a variety of noxious and
inﬂammatory signals, including capsaicin, heat and protons, and are up-regulated under inﬂammatory
conditions. As end-stage kidney disease (ESKD) is associated with chronic inﬂammation, impaired immunity
and depressed lymphocyte numbers, we sought to determine whether altered TRPV1 (and related TRPV2)
expression in immune cells might be a contributing factor. TRPV1 and TRPV2 mRNA expression in
peripheral blood mononuclear cells (PBMC) was similar in controls and ESKD patients by quantitative real-
time RT-PCR. However, using immunocytochemistry, TRPV1-immunoreactivity was signiﬁcantly higher and
TRPV2-immunoreactivity was signiﬁcantly lower in PBMC from ESKD patients compared to controls. The
plant-derived TRPV1 agonists, capsaicin and resiniferatoxin (RTX) and the putative endovanilloid/
endocannabinoids, N-arachidonoyl-dopamine (NADA) and N-oleoyl-dopamine (OLDA), induced concentra-
tion-dependent death of PBMC from healthy donors with a rank order of potency of RTXNNA-
DANOLDANNcapsaicin. TRPV1 (5′-iodoresiniferatoxin) and cannabinoid (CB2; AM630) receptor antagonists
blocked the cytotoxic effect of NADA. In subsequent experiments, PBMC from ESKD patients exhibited
signiﬁcantly increased susceptibility to NADA-induced death compared to PBMC from controls. The apparent
up-regulation of TRPV1 may be a response to the inﬂammatory milieu in which PBMC exist in ESKD and may
be responsible for the increased susceptibility of these cells to NADA-induced death, providing a possible
explanation as to why ESKD patients have reduced lymphocyte counts and impaired immune function. Thus,
TRPV1 (and possibly CB2) antagonists may have potential for the treatment of immune dysfunction in ESKD.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The transient receptor potential (TRP) protein superfamily is a
diverse group of voltage-independent, calcium-permeable cation
channels expressed in mammalian cells that can be classiﬁed into
six related subfamilies [1,2]. The most well known member of the
vanilloid (TRPV) subfamily, TRPV1, is directly activated by vanilloids,
such as capsaicin, moderate heat (≥43 °C), protons (pH≤5.9), bases
(pHN8), bradykinins and some arachidonic acid metabolites, includ-
ing the endogenous vanilloid/cannabinoid N-arachidonoyl-dopamine
(NADA) [2–5]. TRPV1 is also (indirectly) sensitised by a diverse range
of substances including protons, lipoxygenase products, bradykinins,
prostaglandins and a number of cytokines and chemokines, all
generated by inﬂammation [2,6–8]. Hence, TRPV1 acts as a polymodal
detector of noxious and inﬂammatory signals [9]. TRPV2 (also referred613 63243658.
hty).
ll rights reserved.to as vanilloid receptor-like 1, VRL-1) shares ∼49% homology with
TRPV1 and is also a heat-gated channel, albeit with a higher
temperature threshold of ∼52 °C [10]. TRPV2, however, is not
activated by capsaicin or protons [2].
TRPV1 and TRPV2 were once believed to be located exclusively on
neurons, where their function has been studied in great detail. However,
more recent studies have demonstrated TRPV1 in a variety of non-
neuronal cells, including neutrophil granulocytes, keratinocytes and
mast cells from human skin as well as cells of epithelial origin in the
bladder and urethra, gastrointestinal tract, lung and prostate [11–16].
TRPV2 has also been reported in urothelial cells, mast cells and
parenchymal cells of the spleen, lung and intestine [10,17–19]. More-
over, disease-associated increases in TRPV1 mRNA and/or protein
expression have been demonstrated in the cervix (cervical cancer),
urinary bladder (detrusor hyperreﬂexia), gastrointestinal tract (inﬂam-
matory bowel disease), respiratory tract (chronic airway inﬂammatory
disease) and leukocytes (hyposensitive individuals) [20–28], suggesting
a pathological association between TRPV1 and inﬂammation. Studies
also suggest that cells aberrantly expressing TRPV1 display increased
susceptibility to apoptotic agents [13,29,30].
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expressed by peripheral blood mononuclear cells (PBMC), consisting
of lymphocytes (∼83%) and monocytes [31]. Whilst the precise roles
of these receptors remain unclear in these cells, lymphocytes are
crucial cells of the immune system with T cells being associated with
activation of the inﬂammatory response. TRPVs may also be an
important component of the Ca2+ release-activated-Ca2+ (CRAC)
channel, necessary to cause productive T-cell activation, inﬂuence
T-cell signalling and/or mediate apoptosis due to Ca2+ overload
[32–34]. Thus, the presence of TRPV1 (and possibly TRPV2) in PBMC
suggests that these receptors play a role in the detection of inﬂam-
matory signals by lymphocytes and monocytes.
Patients with end-stage kidney disease (ESKD), requiring regular
dialysis treatment, are in a constant state of inﬂammation and oxi-
dative stress, reﬂected by elevated pentraxin levels [e.g., pentraxin-3
(PTX3) and C-reactive protein (CRP)] and other indicators of inﬂam-
mation [e.g., interleukins (IL)-1, 4, 6 and 10 and tumour necrosis factor
alpha (TNF-α)] [35]. In addition, depressed and aberrant cell-mediated
immunity and altered lymphocyte function in chronic kidney disease
have been well documented [36,37], making this patient population
an ideal model to investigate the effects of chronic inﬂammation on
TRPVs in immune system cells. Thus, the aims of the present study
were to compare TRPV1 and TRPV2 mRNA expression and immuno-
reactivity in PBMC from healthy controls and ESKD patients, and to
compare the susceptibility of PBMC from these subjects to vanilloid-
induced death.2. Materials and methods
2.1. Participants
Peripheral blood (8 mL lithium-heparin, 8 mL EDTA) was obtained
from 32 ESKD patients [18 females, 14 males; aged 59±12 years
(mean±SD)] undergoing haemodialysis at Launceston General
Hospital Renal Unit (Launceston, Tasmania, Australia) from either a
ﬁstula or vascular access catheter and 29 age- and gender-matched
control participants (16 females, 13 males; aged 59±11 years) from
either the median or cephalic vein, under resting conditions. Control
participants had no history of kidney disease or recent infection and
were not currently taking anti-inﬂammatory medications. The study
was approved by the Human Research Ethics Committee Network,
Tasmania (H8897). All participating individuals gave informed
written consent.
The primary causes of kidney disease were diabetic nephropathy
(n=9), glomerulonephritis (n=5), reﬂux nephropathy (n=4),
polycystic kidney disease (n=4), hypertension (n=3),miscellaneous
(n=6) and uncertain diagnosis (n=1). Sixty-one percent of ESKD
patients were taking at least one, often a combination of, prescribed
anti-hypertensive medication(s) [calcium channel antagonist
(n=10), angiotensin-converting enzyme inhibitor (n=9), β-blocker
(n=8), angiotensin II receptor blockers (n=5), α-adrenergic blocker
(n=2) and/or endothelin receptor antagonist (n=1)]. Other con-
current medications were: statin (n=8), erythropoietin (n=24),
calcium supplement (n=23), inhaled glucocorticoid (n=4, low
doses as necessary for asthma) and anticoagulant/antiplatelet agents
(n=15; warfarin, aspirin, clopidogrel). Some patients had undergone
prior kidney transplantation (n=8), which remained in situ, however,
due to rejection of the graft these individuals were no longer receiving
immunosuppressive therapy.
All ESKD patients had a urea reduction ratio of N76% (targetN70%).
Pre-dialysis serum creatinine was 752±181 μmol/L; white cell count
was 7.4±2.4×109/L; lymphocyte count was 1.5±0.5×109/L (normal
reference range values are: 50–105 μmol/L; 4.0–11.0×109/L; 1.5–
4.0×109/L, respectively) [38]. Eighty-two percent of patients had CRP
N5 mg/L, an indicator of inﬂammation.2.2. Peripheral blood mononuclear cell preparation
PBMC were isolated as previously described by Duthie et al. [39].
Brieﬂy, peripheral blood was diluted 1:1 with phosphate-buffered
saline (PBS) and separated by centrifugation over Histopaque (Sigma-
Aldrich, St. Louis, U. S. A.) at 700 ×g for 30 min at 20 °C. The
mononuclear layer was collected and centrifuged in RPMI 1640
(Invitrogen, Carlsbad, U. S. A.) at 700 ×g for 15 min at 20 °C. The pellet
was resuspended in RPMI containing 10% foetal calf serum (FCS,
Invitrogen, Carlsbad, U. S. A.). Ten microlitres of cell suspension was
diluted 1:1 with Trypan Blue (Sigma-Aldrich, St. Louis, U. S. A.) and 5
large squares counted using an Improved Nebauer Haemocytometer
(Merck, Lutterwork, UK). The remaining cell suspension was centri-
fuged at 854 ×g for 15 min at room temperature and the pellet
resuspended in 0.5 mL aliquots at a density of 3×106cells/mL in a
freezing mix of 90% v/v heat-inactivated FCS and 10% v/v dimethyl
sulfoxide (DMSO, Sigma-Aldrich, St. Louis, U. S. A.). Suspensions were
frozen at−80 °C using a Nalgene Cryo 1 °C Freezing Container (Thermo
Fisher Scientiﬁc, Rochester, U. S. A.). The isolated PBMC suspension
consisted predominantly of lymphocytes (control participants 87±3%;
ESKD patients 85±4%), determined using a Coulter MaxM haematol-
ogy analyser (Beckman Coulter, Gladesville, Australia).
2.3. RNA extraction from isolated PBMC and reverse transcription
Frozen cell suspensions from EDTA blood were thawed and
centrifuged at 854 ×g for 3 min. Pellets were resuspended with
0.01 M PBS and re-centrifuged. RNA was extracted using the RNeasy
Mini Kit (Qiagen, Hilden, NRW, Germany) according to the manufac-
turer's instructions. The concentration of RNA was measured spectro-
photometrically (Eppendorf Biophotometer, North Ryde, Australia)
and samples stored at −20 °C until use. Five microlitres of RNA
suspension was reverse transcribed using an Omniscript Reverse
Transcriptase (RT) Kit (Qiagen, Hilden, Germany) containing 10× RT
buffer, dNTP-Mix, oligo (dT) primer (Promega, Madison, U. S. A.),
RNase Inhibitor (Promega, Madison, U. S. A.) and Omniscript RT
polymerase. Tubes with reaction mixtures were incubated at 44 °C for
1 h with 10 min inactivation of enzyme at 92 °C and the resultant
cDNA was stored at −20 °C until used for PCR ampliﬁcation.
2.4. Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed using iQ
SYBR Green Supermix (BioRad, Hercules, CA, U. S. A.). The following
primer pairs (Geneworks, Adelaide, Australia) were used: human
TRPV1, forward primer 5′-CAG CAG CGA GAC CCC TAA-3′ (position
1209–1226 in the sequence of human TRPV1) and reverse primer 5′-
CCT GCAGGAGTC GGT TCA-3′ (position 1256–1273 in the sequence of
human TRPV1) and human TRPV2, forward primer 5′-CTA CAG TGT
CAT GAT CCA GAA GGT-3′ (position 1933–1956 in the sequence of
human TRPV2) and reverse primer 5′-CCG AAA AGG AAG ACT AAG
TAG ATC A-3′ (position 1986–2010 in the sequence of human TRPV2).
qRT-PCR assays for each gene target were performed on cDNA samples
and genomic DNA standards in 96-well optical plates on a MyIQ
Single-Colour Real-Time PCR Detection System (BioRad, Hercules,
U. S. A.). Each ampliﬁcation program consisted of: one cycle of 95 °C
for 15 min, followed by 30 cycles of 95 °C at 30 s and 61 °C (TRPV1) or
59 °C (TRPV2) for 30 s and a single cycle of 72 °C for 30 s, 65 °C for
1 min and 65 °C for 10 min. A parallel assay, with an annealing
temperature of 55 °C, was run for the housekeeping gene GAPDH, in
addition to target mRNA of interest.
2.5. TRPV1 and TRPV2 immunocytochemistry
TRPV1- and TRPV2-immunoreactivity present in PBMC was
visualised by indirect immunoﬂuorescence as previously described
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isolated from lithium-heparinised blood (n=20 controls and 20 ESKD
patients), was thawed at 37 °C and centrifuged at 854 ×g for 3 min.
Pellets were resuspended in 0.01 M PBS and re-centrifuged. Non-
speciﬁc antibody binding sites on the mononuclear cells were blocked
by incubating for 1 h at room temperature on a platform mixer (OM6
Orbital Mixer, Ratek, Boronia, Australia) in a solution of 5% bovine
serum albumin (BSA, Sigma-Aldrich, St. Louis, U. S. A.) followed by re-
centrifugation. Pellets were then incubated for 30 min at room
temperature on a platform mixer with either rabbit polyclonal anti-
capsaicin receptor (TRPV1) antisera (1:500, Chemicon International,
Billerica, U. S. A.) or goat polyclonal anti-VRL-1 (TRPV2) antisera
(1:250, Santa Cruz Biotechnology, Santa Cruz, U. S. A.), followed by
incubation at 4 °C overnight. After three washes in 0.01 M PBS, pellets
were incubated with either goat Texas red-labelled anti-rabbit
antibody for TRPV1 detection (1:1000, Molecular Probes, Eugene,
U. S. A.) or a donkey ﬂuoroscein-isothiocyanate-labelled anti-goat
antibody for TRPV2 detection (1:1000, Invitrogen, Carlsbad, U. S. A.)
for 1.5 h at room temperature on a platform mixer, followed by
another three washes in 0.01 M PBS. The ﬁnal supernatants were
discarded and the pellets counterstained with nuclear yellow (0.001%
in PBS, Sigma-Aldrich, St. Louis, U. S. A.) for 5 min, to assess cell
viability. After threewashes in 0.01M PBS, the ﬁnal supernatants were
discarded and the pellets were resuspended in 85 μL low melting
point agarose (LMP, 1% in PBS, Invitrogen, Carlsbad, U. S. A.), mounted
onto standard agarose (1% in PBS, Invitrogen, Carlsbad, U. S. A.) coated
slides and cover-slipped. To test for non-speciﬁc immunoﬂuorescence
produced by the secondary antibodies, primary antibody was
excluded in negative controls. No immunolabelling was observed on
these slides.
Immunostaining of TRPV1 and TRPV2 in PBMC was viewed using
an Olympus IX71 inverted ﬂuorescence microscope (Olympus, Center
Valley, U. S. A.). Fifty cells from each participant were randomly
selected and photographed using an Optronics digital camera
(Optronics, Model 60800, Goleta, U. S. A.). Exposure times were
800 ms for TRPV1 staining and 5.154 s for TRPV2 staining. Images
were captured and saved electronically as tiff ﬁles using MagnaFire
software (version 2.1, Optronics, Goleta, U. S. A.). Unmodiﬁed images
were converted to grey scale and inverted so that ﬂuorescence
appeared as black on a white background. TRPV1- and TRPV2-
immunoreactivity in small (∼5–8 μm) and large (∼10–17 μm)
mononuclear cells was quantitated using image analysis software
(AIS, version 3.0, Imaging Research, St. Catharines, Canada). Detec-
tion was set above background. The intensity of immunoreactivity
was deﬁned as the product of relative optical density (ROD) and area
of immunoreactivity.
2.6. Vanilloid/endovanilloid-induced PBMC death
Peripheral blood from healthy, adult donors (n=3) was collected
into EDTA tubes and PBMC isolated as previously stated. Frozen cell
suspensions were thawed at 37 °C and centrifuged at 854 ×g for 3min.
Pellets were washed twice in 500 μL RPMI containing 10% FCS at
854 ×g for 3 min. Cell viability was determined by Trypan Blue
exclusion [40]. Brieﬂy, 10 μL of cell suspension was diluted 1:1 with
Trypan Blue and 5 large squares counted using an Improved Nebauer
Haemocytometer. Samples with less than 80% viability were dis-
carded. Cells were resuspended in 500 μL complete RPMI containing
2 mM L-glutamine, 100 U Penicillin, 100 U Streptomycin (Invitrogen,
Carlsbad, U. S. A.) and 10% FCS in 24-well cell culture plates (Greiner
Bio-One, Frickenhausen, Germany).
NADA, capsaicin, resiniferatoxin (RTX) and N-oleoyl-dopamine
(OLDA) (Tocris Bioscience, Ellisville, U. S. A.) were reconstituted in
ethanol to a stock concentration of 11 mM, 50 mM, 10 mM and 2 mM,
respectively. Suspensions of PBMC (∼1×105 cells/mL) were incu-
bated with NADA (3.4–100 μM), capsaicin (15–500 μM), RTX (1.5–50 μM), OLDA (10–100 μM) or vehicle (0.2% ethanol) for 24 h at 37 °C
in 8% CO2 in a Heraeus HERAcell 150 incubator (Thermo Fisher
Scientiﬁc, Rochester, U. S. A.). Cell suspensions were then centrifuged
at 854 ×g for 3 min. Pellets were washed twice in 500 μL RPMI
containing 10% FCS at 854 ×g for 3 min. Cell viability was determined
by Trypan Blue exclusion. Cell viability, normalised to pre-exposure
cell viability (expressed as a percentage) was plotted against log
[agonist] and the concentration of each agonist required to reduce cell
viability by 50% (EC50) was determined.
The EC50 for NADA-induced PBMC death was 29 μM (see Results).
As NADA is an endogenous activator of TRPV1 and also relatively
soluble in aqueousmedia, we employed 25 μMNADA in all subsequent
experiments including antagonist studies and comparisons between
healthy controls and ESKD patients.
The receptors responsible for NADA-induced cytotoxicity were
further investigated using TRPV1 and cannabinoid (CB) antagonists.
Frozen cell suspensions from EDTA blood of healthy adult donors used
abovewere thawed, washed, viability determined and resuspended in
incubation medium as previously described,. The TRPV1 antagonists,
5′-iodoresiniferatoxin (IRTX) and capsazepine (CPZ) (Tocris
Bioscience, Ellisville, U. S. A.), were dissolved in ethanol. The CB1
antagonist, N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophe-
nyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) and CB2 antago-
nist, 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-
methoxyphenyl) methanone (AM630) (Tocris Bioscience, Ellisville,
U. S. A.), were dissolved in DMSO to a stock concentration of 3mM and
3.5 mM, respectively. The ﬁnal concentrations of IRTX (100 nM), CPZ
(1 μM), AM251 (500 nM) and AM630 (1 μM) employedwere based on
previous studies [41–48]. NADA (25 μM), vehicle (0.2% ethanol or
0.03% DMSO), IRTX (100 nM), CPZ (1 μM), IRTX+NADA (100 nM and
25 μM, respectively), CPZ+NADA (1 μM and 25 μM, respectively),
AM251 (500 nM), AM630 (1 μM), AM251+NADA (500 nM and 25 μM
respectively), AM630+NADA (1 μM and 25 μM respectively) or IRTX+
AM630+NADA (100 nM, 1 μM and 25 μM respectively) were added to
the cell suspensions (n=3 for all combinations). NADA was added
30 min after antagonists. Samples were incubated for 24 h at 37 °C in
8% CO2 in a Heraeus HERAcell 150 incubator. Cell suspensions were
processed as described earlier. Post-exposure cell viability was normal-
ised to pre-exposure cell viability (expressed as a percentage).
Finally, frozen cell suspensions from EDTA blood from ESKD
patients and age- and gender-matched controls were thawed, washed,
viability determined and resuspended in incubation medium as
previously described. NADA (25 μM, n=7 controls and 7 ESKD
patients) or vehicle (0.2% ethanol, n=3 controls and 3 ESKD patients)
was added to cell suspensions. Samples were incubated for 24 h at
37 °C in 8% CO2 in a Heraeus HERAcell 150 incubator. Cell suspensions
were processed as previously described. Post-exposure cell viability
was normalised to pre-exposure cell viability (expressed as a
percentage).
2.7. Statistical analysis
All qRT-PCR data were captured using MyIQ Single-Colour Real-
Time PCR Detection System Software (version 1.0, BioRad, Hercules,
U. S. A.). Using the standard curve generated with DNA plasmid
templates, the threshold cycle value for each cDNA samplewas used to
calculate the initial quantity of cDNA template per well. Data from
each well was normalised by dividing the quantity of target gene
cDNA by the quantity of GAPDH cDNA and expressed as copies per 106
copies of GAPDH to correct for differences in RNA quantity and quality.
Simple linear regression analysis (Prism, v4.0, GraphPad Software,
San Diego, U. S. A.) was performed to determine relationships
between TRPV1/2 mRNA and immunoreactivity, and age in both
controls and ESKD patients, and TRPV1/2 mRNA and immunoreactiv-
ity, and time spent undergoing dialysis treatment, estimated glomer-
ular ﬁltration rate (eGFR), CRP, urea and creatinine levels in ESKD
Fig. 2. Relationship between age and TRPV1 or TRPV2 mRNA expression in PBMC of
controls and ESKD patients. The correlation between age and (A) TRPV1 or (B) TRPV2
mRNA expression in PBMC of controls (n=29) and ESKD patients (n=32) was
analysed using linear regression (r2, correlation coefﬁcient). mRNA is expressed as
copies per 106 copies of the housekeeping gene, GAPDH.
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version 9.0, StataCorp LP, College Station, U. S. A.), with adjustment for
potential confounders by inclusion of covariates, was also employed.
Unpaired t-tests were used to determine whether there were any
signiﬁcant differences in TRPV1 and TRPV2 mRNA/immunoreactivity
between controls and ESKD patients, gender in both groups and the
mode of blood collection, CRP levels and prescribedmedications in the
ESKD patients.
Nonlinear regression was used to determine the EC50 value for
TRPV1 agonists (Prism). Unpaired t-test was used to determine the
effect of TRPV1 antagonists on NADA-induced PBMC death. pb0.05
was considered statistically signiﬁcant for regression and comparison
analyses and pb0.01 was considered statistically signiﬁcant for
associations. Data are presented as mean and standard error of
mean (SEM).
3. Results
3.1. TRPV1 and TRPV2 mRNA expression in PBMC
TRPV1 expression was ∼130-fold lower than TRPV2 expression in
both control participants and ESKD patients (Fig. 1). However, there
were no signiﬁcant differences in TRPV1 (Fig. 1A) or TRPV2 (Fig. 1B)
mRNA expression between controls and ESKD patients. Expression of
the housekeeping gene, GAPDH, was also not signiﬁcantly different
between control participants and ESKD patients (Fig. 1C).
Interestingly, TRPV1mRNAwas inversely related to age (Fig. 2A) in
both controls (p=0.047) and ESKD patients (p=0.056). However,
there was no signiﬁcant relationship between TRPV2mRNA and age in
either the control group (p=0.064) or ESKD patients (p=0.607;
Fig. 2B). Statistical analysis demonstrated no signiﬁcant relationshipFig. 1. TRPV1, TRPV2 and GAPDH mRNA expression in PBMC of controls and ESKD
patients. (A) TRPV1 (B) TRPV2 and (C) GAPDH mRNA expression in PBMC of controls
(n=29) and ESKD patients (n=32) was analysed by quantitative real-time RT-PCR.
mRNA for TRPV1 and TRPV2 is expressed as copies per 106 copies of the housekeeping
gene, GAPDH. Data are presented as mean±SEM.between TRPV1 or TRPV2 mRNA and gender in either group. In
addition, for ESKD patients, there were no associations between
TRPV1 or TRPV2 mRNA copy number and the duration of dialysis
therapy, whether the blood sample was obtained from a ﬁstula or
vascular access catheter, prescribed medications, biochemical para-
meters, such as serum creatinine and CRP, or cause of kidney disease.
3.2. TRPV1- and TRPV2-immunoreactivity
Non-speciﬁc immunoﬂuorescence produced by the secondary
antibodies was negligible for both the TRPV1 and TRPV2 antibodies
(negative control, Fig. 3). The intra-sample intensity of TRPV1-
immunoreactivity in PBMC varied greatly in both controls and ESKD
patients (ROD×area ranged from N0.001–13.82 and N0.001–20.41,
respectively). Up to 42% of cells from individual control participants
and up to 60% of cells from individual ESKD patients (15±14% andFig. 3. Photomicrographs of TRPV1- and TRPV2-immunoreactivity in PBMC of a control
participant. Photomicrographs are black and white conversions of coloured (unmodi-
ﬁed) TRPV1 and TRPV2 ﬂuorescent images. Lanes 1–4 demonstrate the variation in
TRPV1- and TRPV2-immunoreactivity from low (lane 1) to high (lane 4). (A) TRPV1-
immunoreactivity in PBMC was greater and more concentrated than (B) TRPV2-
immunoreactivity in both controls and ESKD patients. Scale bar=10 μM.
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contrast, whilst the intra-sample level of TRPV2-immunoreactivity
also varied in both controls and ESKD patients (b0.001–0.08 in both
groups), ﬂuorescence was much less intense and not localised to a
deﬁnable cellular compartment or structure. A representative image
of the variation in TRPV1- and TRPV2-immunoreactivity in PBMC
from a control participant is provided (Fig. 3).
The intensity of TRPV1-immunoreactivity in PBMC from patients
with ESKD was signiﬁcantly (pb0.001) greater (92%) than that of
controls (Fig. 4A). TRPV2-immunoreactivity was signiﬁcantly
(p=0.003) lower (28%) in PBMC from patients with ESKD when
compared to controls (Fig. 4B).
The isolated PBMC suspensions, after thawing, consisted predo-
minantly of lymphocytes (control participants 87±3%; ESKD patients
85±4%). Two distinct subsets of lymphocytes exist, large lympho-
cytes and small lymphocytes. The majority of large lymphocytes are
natural killer cells and the small lymphocytes consist of T and B cells. A
small lymphocyte may also become a large lymphocyte as it is
stimulated to proliferate (e.g., bymitogens such as PHA or binding of a
speciﬁc antigen) [49]. To determine whether these observed changes
in TRPV1- and TRPV2-immunoreactivity were limited to a speciﬁc
PBMC size, the intensity of TRPV1- and TRPV2-immunoreactivity in
the two cell subgroups was compared based on their size (small PBMC
∼5–8 μm; large PBMC ∼10–17 μm; Fig. 4). TRPV1-immunoreactivity in
both small and large PBMC of controls and ESKD patients was similar
(Fig. 4A). In contrast, the lower overall TRPV2-immunoreactivity
observed in PBMC from ESKD patients was due primarily to a decrease
in immunoreactivity expressed by small PBMC (Fig. 4B).
Regression analysis revealed no relationship between TRPV1
(n=20 controls and 20 ESKD patients; aged 35 to 78 years) or
TRPV2 (n=10 controls and 10 ESKD patients; aged 46 to 78 years)
immunoreactivity with age in controls (r2=0.001, p=0.953 and
r2=0.041, p=0.574, respectively) or ESKD patients (r2=0.001,Fig. 4. Quantitation of TRPV1- and TRPV2-immunoreactivity in PBMC of controls and
ESKD patients. The intensity of (A) TRPV1- and (B) TRPV2-immunoreactivity (relative
optical density×area) in PBMC from control participants (white bars) and ESKD
patients (black bars). Fifty cells from each participant were randomly selected and
photographed. PBMC were subsequently classiﬁed as either small (∼5–8 μm) or large
(∼10–17 μm) and the intensity of (A) TRPV1- and (B) TRPV2-immunoreactivity calculated.
TRPV1; n=20 controls and 20 ESKD patients, TRPV2; n=10 controls and 10 ESKD
patients,⁎ denotes pb0.05 compared to controls. Data are presented as mean±SEM.
Fig. 5. Vanilloid-induced PBMC death. (A) Log-concentration-response curves for
N-arachidonoyl-dopamine (NADA)-, N-oleoyl-dopamine (OLDA)-, capsaicin (CAP)-
and resiniferatoxin (RTX)-induced death of PBMC from healthy adult donors. PBMC
were exposed to increasing concentrations of NADA (3.4–100 μm), CAP (15–500 μm),
RTX (1.5–50 μm) or OLDA (10–100 μm) for 24 h. Each point represents the mean±
SEM of n=3 experiments. Where error bars are absent they are within symbols. (B)
Effect of TRPV1, CB1 and CB2 antagonists on NADA-induced PBMC death. Cell viability
studies were performed with the TRPV1 antagonists, 5′-iodoresiniferatoxin (IRTX,
100 nM) and capsazepine (CPZ, 1 μM), a CB1 antagonist, AM251 (500 nM), and a CB2
antagonist, AM630 (1 μM). PBMC from healthy adult donors were incubated for 24 h
with either vehicle (0.2% ethanol, V, white bar), NADA (25 μM, N, black bar),
antagonist alone (white bar) or antagonist in the presence of NADA (black bar). Bars
represent the mean±SEM (vehicle and NADA; n=6, antagonists and antagonists+
NADA; n=3). ⁎ denotes pb0.05 compared with vehicle; # denotes pb0.05 compared
with antagonist alone; † denotes pb0.05 compared with NADA alone. (C) NADA-
induced PBMC death in controls and ESKD patients. Cell viability studies were
performed on PBMC from controls and ESKD patients using 24 h exposure to either
vehicle (0.2% ethanol, white bars) or NADA (25 μM, black bars). Bars represent the
mean±SEM (vehicle; n=3 controls and 3 ESKD patients, NADA; n=7 controls and 7
ESKD patients, ⁎ denotes pb0.05 compared with vehicle; # denotes pb0.05 compared
with controls. In all experiments, cell viability was determined by Trypan Blue exclusion
and normalised to pre-exposure cell viability (expressed as a percentage).p=0.902 and r2=0.285, p=0.112, respectively). There was no
statistically signiﬁcant relationship between TRPV1 or TRPV2 mRNA
and gender in either group. Similarly, there were no associations
between TRPV1 or TRPV2-immunoreactivity and duration of dialysis
therapy, the mode of blood collection, prescribed medications,
biochemical parameters or cause of kidney disease in ESKD patients.
There was no relationship between TRPV1 mRNA and TRPV1-
immunoreactivity or TRPV2 mRNA and TRPV2-immunoreactivity in
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(TRPV1, p=0.374; TRPV2, p=0.987).
3.3. Vanilloid/endovanilloid-induced PBMC death
Exposure of PBMC from healthy adult donors to putative endogen-
ous TRPV1 activators (NADA and OLDA), and the ‘classical’ plant-
derived activators, capsaicin and RTX, for 24 h produced concentration-
dependent decreases in cell viability (Fig. 5A). The rank order of potency
of these agents (EC50, μM, n=3–4 experiments) was RTX (21±1)N
NADA (29±1)NOLDA (40±1)NNcapsaicin (240±1). The slopes of the
concentration-response curves for all four TRPV1 activators were
extremely steep, ranging from−3 to −9.
Exposure of PBMC suspensions to TRPV1 and CB receptor
antagonists alone had no effect on cell viability (Fig. 5B). The TRPV1
selective and CB2 selective antagonists, IRTX and AM630, respectively,
almost completely blocked NADA (25 μM)-induced cell death.
Incubation with both IRTX and AM630 produced no additional
inhibition. However, the cytotoxic effect of NADAwas not antagonised
by the functional TRPV1 antagonist, CPZ, or the selective CB1
antagonist, AM251 (Fig. 5B). In fact, NADA combined with CPZ or
AM251 appeared to be more cytotoxic to PBMC (p=0.029 and
p=0.007, respectively) when compared to NADA alone (Fig. 5B).
PBMC viability after incubationwith NADAwas determined in seven
ESKD patients and age- and gender-matched control participants.
TRPV1-immunoreactivity in the PBMC from ESKDpatients used in these
NADA studies was signiﬁcantly (p=0.015) greater than that of
corresponding controls. Cell viability after 24 h exposure to NADA was
signiﬁcantly (p=0.003) lower (17%) in ESKD patients compared with
controls (Fig. 5C).
When data from both controls and ESKD patients were combined,
there was a highly signiﬁcant (p=0.006) negative association
between TRPV1-immunoreactivity and cell viability (r2=0.484).
4. Discussion
We have previously reported that both TRPV1 and TRPV2 are
present in PBMC of healthy adults [31]. In the present study, we
extended that work and used qRT-PCR, immunocytochemistry and an
in vitro cell viability assay to determine whether TRPV1 (and TRPV2)
in PBMC are affected by the inﬂammatory state associated with ESKD.
There was no difference in TRPV1, TRPV2 or GAPDH mRNA
expression in PBMC from ESKD patients compared to controls.
TRPV1 mRNA expression decreased with age in both controls and
ESKD. It is well-documented that immune, in particular lymphocyte,
function declines with age [50–52]. However, whether this result is
merely coincidental or there is a true link between TRPV1 and
declining immune function with age has yet to be investigated.
The intensity of both TRPV1 and TRPV2 immunoﬂuorescence
varied between PBMC from the same individual. This may be due to
unique subsets of mononuclear cells, e.g., lymphocytes and mono-
cytes, expressing TRPV1 or TRPV2 protein to differing degrees. Indeed,
we have preliminary data that showmonocyte TRPV1 and TRPV2mRNA
expression and immunoreactivity are signiﬁcantly lower in monocytes
compared to lymphocytes in healthy individuals (Kunde D,Whitmore B,
Geraghty D, unpublished observations). In addition, detailed studies
into TRPV expression by cell subsets (T, B and natural killer cells and
monocytes) using ﬂow cytometric analysis are underway.
TRPV1-immunoreactivity in both small and large PBMC of ESKD
patients was signiﬁcantly higher compared to controls. In contrast,
TRPV2-immunoreactivity was signiﬁcantly lower in ESKD patients
compared to controls and was conﬁned to small PBMC. Given that
these differences in TRPV1- and TRPV2-immunoreactivity in PBMC
from ESKD patients were not related to TRPV1 and TRPV2 mRNA
expression, respectively, TRPV1 and TRPV2 protein may be recipro-
cally regulated in PBMC of ESKD patients. Interestingly, Ji et al. [53]have reported that inﬂammation increases cell surface expression of
TRPV1 by rat DRG neurons, with no change in TRPV1 mRNA
expression. Thus, inﬂammation/disease may affect translation, rather
than transcription, of TRPV1 and TRPV2.
TRPV1 or TRPV2 mRNA expression and immunoreactivity were
unrelated to the time (months) spent undergoing dialysis treatment,
the mode of blood collection, gender, prescribed medications,
biochemical parameters or cause of kidney disease. Thus, the changes
reported in TRPV1- (and TRPV2-) immunoreactivity in ESKD patients
may be a consequence of chronic inﬂammation. Indeed, the high CRP
levels (N5 mg/L) recorded in the majority (82%) of ESKD patients in
this study are indicative of an inﬂammatory state. Inﬂammation
associated with ESKD may trigger up-regulation of TRPV1 and
supports previous studies that demonstrated increases in TRPV1
mRNA and/or immunoreactivity in a variety of inﬂammatory condi-
tions [20–27], thus, providing further evidence for a pathological
association between increased TRPV1 expression and inﬂammation.
In order to conﬁrm TRPV1 and TRPV2 protein expression in PBMC of
control participants and ESKD patients, a Western Blot analysis
protocol is currently being designed in our laboratory.
Changes to cell surface receptors and signalling events in PBMC
from ESKD patients on haemodialysis have previously been reported
[54–56]. Depressed proliferative responses to the T-cell mitogens
phytohemagglutinin and concanavalin A and increased expression of a
distinct V-region of the β-chains of the T-cell receptor antigen
receptor (Vβ6.7) have shown to be increased in CKD patients
compared to controls [55,56]. In addition, several groups have
demonstrated an increased expression of the interleukin 2 receptor
(IL-2R), critical for T-cell proliferation, on PBMC from patients
undergoing dialysis. Evidence that heightened expression of IL-2R is
linked to immunodeﬁciency has also been reported [54], supporting
the depressed and aberrant cell-mediated immunity and altered
lymphocyte function in CKD, which is well documented [36,37].
Due to the paucity of studies addressing the function(s) and
regulation of TRPV2, we cannot currently explain the mechanism
behind, or the functional consequences of, TRPV2 down-regulation in
PBMC of ESKD patients. TRPV1, however, is a vital component of
mammalian sensory function and while deﬁnitive physiological
functions of TRPV1 and the consequences of activation in PBMC
have not been established, TRPV1 has been implicated as a key
mediator of various cellular responses to vanilloids in vivo and in vitro
and several studies have demonstrated that TRPV1 mediates cell
death in a variety of cell types, including human neuroblastoma and
lymphoma cell lines and TRPV1-transfected human kidney cells
[13,29,30,57].
In preliminary experiments, concentration-dependent PBMC
death following exposure to the endovanilloid/endocannabinoids,
NADA and OLDA, and the plant-derived TRPV1 activators, capsaicin
and RTX, was demonstrated, further supporting the presence of TRPV1
in these cells. Moreover, RTX was N10-fold more potent than capsaicin
at inducing PBMC death, indicative of the ‘classical’ TRPV1 receptor.
The relatively high EC50s for NADA (∼30 μM) and OLDA (40 μM)
should not be seen as evidence against a physiological role for TRPV1
on PBMC. N-arachidonoylethanolamine (AEA), the ﬁrst endovanil-
loid/cannabinoid to be described, induces apoptosis with an EC50
ranging from 2–20 μM, depending on the cell type/line [13,21,58,59].
Moreover, the threshold for TRPV1 activation by AEA and other
agonists is signiﬁcantly lowered by several other regulatory factors,
including protein kinase C, which can be activated by a diverse range
of substances including bradykinins, acidic pH and prostaglandins, all
generated by inﬂammation [60,61].
NADA-induced PBMC death was mediated by TRPV1 and CB2
receptors, as prior exposure to the TRPV1 antagonist, IRTX, and the CB2
receptor antagonist, AM630 (but not the CB1 receptor antagonist,
AM251), almost completely blocked the cytotoxic effect. Whilst NADA
is 50-fold more potent at CB1 compared with CB2 receptors (Ki values
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in the brain, while CB2 receptors are known to be expressed on various
types of cells in the immune system including B-lymphocytes, natural
killer cells and macrophages [62]. An involvement of CB2 receptors in
the regulation of inﬂammation and immunity is widely accepted [63].
Furthermore, activation of CB2 receptors by AEA has been shown to
suppress immune function [64]. The present study suggests that a
combination of TRPV1- and CB2 receptor-mediatedmechanismsmay be
required for NADA-induced PBMC death.
Interestingly, CPZ (at the concentration employed; 1 μM) was
without effect on NADA-induced PBMC death. TRPV1 agonist-induced
increases in intracellular Na+ and tetramerisation of TRPV1 subunits
at the plasma membrane level have both been suggested as possible
mechanisms of cell death. However, they have both been shown to be
blocked by CPZ [65,66]. Reilly et al. [67] have also presented data that
highlight the existence of a TRPV1-mediated process that ultimately
leads to cell death in a TRPV1-overexpressing bronchial epithelial cell
line, which can be inhibited by IRTX (0.1–1 μM), but not CPZ (0.01 to
∼50 μM). The authors proposed that cell death may also occur via the
activation of intracellular, ER-bound TRPV1, accessible only by IRTX, to
promote vanilloid-induced toxicity.
Given the markedly increased expression of TRPV1-immunoreac-
tivity in PBMC from ESKD patients, the effect of NADA on PBMC
viability in ESKD patients was compared to control participants. PBMC
from the ESKD patients demonstrated signiﬁcantly increased suscept-
ibility to in vitro NADA-induced cytotoxicity compared to controls,
which was signiﬁcantly related to an increase in TRPV1-immunor-
eactivity. This is comparable to other studies which have reported that
cells overexpressing TRPV1 are more susceptible to vanilloid-induced
cell death [13,21,58,68,69]. Whilst construction of full concentration-
effect curves for TRPV1 agonists, and the effects of TRPV1, CB1 and CB2
receptor antagonists on NADA-induced PBMC death, in both ESKD and
controls would have been appropriate, due to the limited supply of
PBMC from both groups and the fact that several ESKD patients died
within six months of PBMC being obtained, PBMC death was assessed
using only a single (∼EC50) concentration of NADA and antagonist
studies were not performed. As NADA-induced PBMC death in healthy
donors could be blocked by the TRPV1 and CB2 receptor antagonists,
IRTX and AM630, respectively, without CB2 immunocytochemistry a
contribution of increased CB2 receptor expression cannot be ruled out
in the present study. Nevertheless, there is minimal amino acid
sequence homology between TRPV1 (particularly the sequence used
to raise the antibody) and the CB2 receptor. Moreover, the direct
relationship between TRPV1 overexpression and NADA cytotoxicity is
supported by the fact that there was a strong negative association
between TRPV1-immunoreactivity and cell viability following expo-
sure to NADA. Whilst it is not possible to compare the effect of NADA
exposure on PBMC of ESKD patients with equivalent TRPV1-immuno-
reactivity to controls to deﬁnitively determinewhether the increase in
PBMC death is due to an increase in TRPV1-immunoreactivity, it
would be prudent to perform Ca2+ ﬂux studies to further elucidate the
mechanism of NADA-induced PBMC death.
In conclusion, the present study suggests that the endovanilloid/
cannabinoid, NADA, induces PBMC death by a mechanism that
involves both TRPV1 and CB2 receptors. PBMC from ESKD patients
overexpress TRPV1 protein (increased TRPV1-immunoreactivity) but
not message, which in turn enhances NADA-induced death of these
cells. This ﬁnding may provide a novel explanation as to why ESKD
patients have reduced lymphocyte counts and impaired immune
function. Thus, TRPV1 or CB2 antagonists may have potential for the
treatment of immune dysfunction in ESKD patients.
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